The CORT model of OAB and depression utilized in our current studies has proven to be a dependable framework for evaluating the potential of a given substance in treating OAB with concurrent depressive symptoms, as evidenced by the results of our earlier investigations. The gene discussed is CORT; the disease is depressive symptom measurement.